-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 19, 2021, Compugen announced that in patients with advanced solid tumors, the Phase 1/2 dose escalation trial of its triple therapy combination has completed the first patient's administration
PVRIG is a new B7/CD28-like immune checkpoint protein, and PVRL2 is the ligand of PVRIG
TIGIT is an inhibitory receptor protein mainly expressed on the surface of T cells and natural killer (NK) cells.
In addition, Compugen has determined that PVRIG and TIGIT are key parallel and complementary inhibitory pathways in the DNAM pathway
▲Blocking PVRIG and TIGIT can produce synergistic effects (picture source: Compugen official website)
COM701 is a humanized antibody that can bind to PVRIG with high affinity, thereby blocking its interaction with the ligand PVRL2
BMS-986207 is a Bristol-Myers Squibb antibody drug under development that targets TIGIT.
Note: The original text has been deleted
Reference materials:
[1] Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207.
